Reuters logo
BUZZ-India's Aurobindo Pharma hits more than 2-mth low on US FDA observations
April 19, 2017 / 9:50 AM / 8 months ago

BUZZ-India's Aurobindo Pharma hits more than 2-mth low on US FDA observations

** Shares of Aurobindo Pharma Ltd fall as much as 5.01 pct to lowest since Feb. 16; top pct loser on NSE index

** U.S. Food and Drug Administration (U.S. FDA) issues Form 483 with six observations after inspection at Aurobindo's formulations making unit in Hyderabad, from April 10-18 (bit.ly/2pQKh7J)

** Aurobindo says observations are all on “procedural improvements,” adds none related to “data integrity”

** An FDA Form 483 is issued to companies when the investigator has observed conditions that may constitute violations of the U.S. Federal Food, Drug and Cosmetic Act, 1938

** Stock has fallen 0.75 pct this year up to Tuesday’s close

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below